Avaleht/Aktsiad/STTK

STTK

USD

Shattuck Labs Inc. Common Stock

$1.930-0.030 (-1.531%)

Reaalajas hind

Healthcare

Biotehnoloogia

Ameerika Ühendriigid

Hinnagraafik

Loading Chart...

Põhinäitajad

Turunäitajad

Ettevõtte fundamentaalnäitajad

Kauplemisstatistika

Turunäitajad

Avatud

$1.960

Kõrge

$2.075

Madal

$1.858

Maht

0.10M

Ettevõtte fundamentaalnäitajad

Turukapitalisatsioon

92.5M

Tööstusharu

Biotehnoloogia

Riik

United States

Kauplemisstatistika

Keskmine maht

0.81M

Börs

NMS

Valuuta

USD

52 nädala vahemik

Madal $0.692Praegune $1.930Kõrge $2.705

Seotud uudised

8. sept 2025 · 13:07

Analyst Upgrades

Wedbush Initiates Coverage On Shattuck Labs with Outperform Rating, Announces Price Target of $4

Wedbush analyst David Nierengarten initiates coverage on Shattuck Labs with a Outperform rating and announces Price Target of $4.

Vaata rohkem

Wedbush Initiates Coverage On Shattuck Labs with Outperform Rating, Announces Price Target of $4

26. aug 2025 · 10:30

GlobeNewswire

Shattuck Labs Announces Closing of up to $103 Million Private Placement and Appointments to Board of Directors

— Aggregate net proceeds from private placement expected to fund SL-325 through multiple Phase 2 clinical trials, including in Inflammatory Bowel Disease (IBD) and potentially another autoimmune disease — — Pro forma

Vaata rohkem

Shattuck Labs Announces Closing of up to $103 Million Private Placement and Appointments to Board of Directors

21. aug 2025 · 14:17

GlobeNewswire

Shattuck Labs Announces IND for SL-325 Is in Effect for the Treatment of Inflammatory Bowel Disease

– SL-325 is a potentially first-in-class DR3 antagonist antibody being developed for the treatment of Inflammatory Bowel Disease (IBD) and other inflammatory and immune-mediated diseases – – The Company is on track to

Vaata rohkem